Volume 95 Issue 46 | p. 11 | News of The Week
Issue Date: November 20, 2017 | Web Date: November 14, 2017

Bayer, Loxo to jointly develop TRK inhibitors

Cancer drug pact could be worth up to $1.5 billion
Department: Business
Keywords: Oncology, Loxo, larotrectinib, TRK inhibitor

In a deal worth up to $1.5 billion, Bayer and Loxo Oncology will jointly develop two Loxo drug candidates, larotrectinib and LOXO-195, for treating cancers caused by a rare genetic mutation. Loxo gets $400 million upfront; the remainder of the money is tied to the approval and sale of the two compounds.

Larotrectinib and the follow-on compound LOXO-195 both block TRK gene fusions, a chromosomal mismatch found in less than . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society